Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALD-401
- Development stage
- Discontinued
- Lead developer
- Cytomedix
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
ALD-401 is an autologous stem cell therapy developed for the treatment of ischemic stroke. The therapy utilizes a proprietary technology to isolate and concentrate a specific population of adult stem cells from the patient's own bone marrow known as ALDH-bright (ALDHbr) cells. These cells are characterized by high levels of the enzyme aldehyde dehydrogenase (ALDH), which serves as a marker for progenitor cells with potent regenerative, angiogenic, and neuroprotective properties. ALD-401 is administered via intracarotid infusion, typically within two to three weeks following a stroke, to promote tissue repair and functional recovery. Originally developed by Aldagen, the program was acquired by Cytomedix (later Nuo Therapeutics) in 2012 and reached Phase 2 clinical trials before being discontinued in 2014 due to strategic resource reallocation.
- Other names
- ALDHbr cellsALDH bright cells
Beyond the preview
Go deeper on ALD-401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALD-401.